Imatinib (IM) versus hydroxychloroquine (HCQ) and IM for patients with chronic myeloid leukaemia (CML) in cytogenetic response (CyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR)

2012 ◽  
Author(s):  
Tessa Holyoake
Sign in / Sign up

Export Citation Format

Share Document